Prevention & lipidsRandomised controlled trial
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
- Randomised controlled trial
- double-blind
- placebo-controlled
- dose-ranging
Authors' conclusion
APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease.
Study context
- Population
- Patients with established CVD and screening lipoprotein(a) ≥60 mg/dL (150 nmol/L)
- Participants
- 286 patients
- Comparison
- APO-LRx at several doses vs placebo
- Primary endpoint
- Percent change in lipoprotein(a) from baseline
- Follow-up
- Month 6 of exposure (week 25 monthly dosing; week 27 more frequent dosing)
Primary result
As reported in the abstract
Percent change in lipoprotein(a) · month 6
Safety
Platelet counts, liver and renal measures, influenza-like symptoms
- No significant differences between any APO(a)-LRx dose and placebo
Adverse events
- Most common AEs were injection-site reactions
Original publication
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. Published 1 January 2020. doi:10.1056/nejmoa1905239
Summarised from the published abstract; every number is checked against it